Clinical course of acute adenoviral conjunctivitis under various drug therapy regimens
DOI: 10.32364/2311-7729-2025-25-1-9
E.A. Kleshcheva1–3
1Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation
2S.P. Botkin City Clinical Hospital, Moscow, Russian Federation
3Herpetic Center LLC, Moscow, Russian Federation
Aim: to determine a clinical course of acute adenoviral conjunctivitis under various drug therapy regimens.
Materials and Methods: 46 subjects (29 females and 17 males; average age — 43.3±11.8 years) with acute adenoviral conjunctivitis were enrolled in the study. Clinical observation represented identification and evaluation of adenoviral eye infection symptom severity. Severity of each symptom was scored in a certain way: 1 score — mild, 2 scores — moderate, and 3 scores — severe. Such signs as petechial subconjunctival hemorrhages, superficial point corneal erosions, as well as fibrous films on the conjunctiva of eyelids and fornices were evaluated according to presence or absence of the symptom. The scores for each feature were summed up to calculate a mean value, and the results were used to compare a clinical course of adenoviral conjunctivitis between groups receiving different topical therapy regimens. A Group I (n=23) received a high-molecular fraction of polysaccharides extracted from Solanum tuberosum shoots, bromphenac, and picloxydine as part of the topical therapy. A Group II (n=23) received human recombinant interferon α-2b, bromphenac, and picloxydine. On average, control visits were conducted once a week.
Results: during initial presentation, the clinical picture of adenoviral conjunctivitis in the study groups was associated with predominance of moderate and severe symptoms reported in more than 90% of cases. There was no a significant difference in severity of clinical symptoms between the Groups I and II before the start of the therapy. Both in the Group I and the Group II, more than 45% of subjects demonstrated high severity of all the manifestations of adenoviral eye infection. The prescribed topical therapy led to a decreased severity of inflammation symptoms in both groups already on the second visit. However, there was a significant difference (p≤0.05) in mean symptom severity between the Groups I and II on the second visit (1.68 and 2.13, respectively). On the third visit, the mean score sum decreased to 0.72 in the Group I which was significantly different (p≤0.05) from the value reported in the Group II (1.56).
Conclusions: a high-molecular-weight fraction of polysaccharides extracted from Solanum tuberosum shoots added in the topical therapy for adenoviral conjunctivitis accelerates inflammatory regression due to antiviral, anti-inflammatory, and immunomodulatory effects of the drug.
Keywords: adenovirus, adenoviral conjunctivitis, Solanum tuberosum polysaccharides.
For citation: Kleshcheva E.A. Clinical course of acute adenoviral conjunctivitis under various drug therapy regimens. Russian Journal of Clinical Ophthalmology. 2025;25(1):60–65 (in Russ.). DOI: 10.32364/2311-7729-2025-25-1-9
About the author:
Elena A. Kleshcheva — C. Sc. (Med.), Assistant Professor, Assistant Professor of the Department of Ophthalmology, Russian Medical Academy of Continuous Professional Education; 2/1, Barrikadnaya str., Moscow, 125993, Russian Federation; Ophthalmologist, S.P. Botkin City Clinical Hospital; 5, 2nd Botkinskiy pass., Moscow, 125284, Russian Federation; Ophthalmologist, Herpetic Center LLC; 10A, building 2, Grimau str., Moscow, 117036, Russian Federation; ORCID iD 0000-0002-1392-3432
Contact information: Elena A. Kleshcheva, e-mail: klelen@mail.ru
Financial Disclosure: the author has no a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 15.12.2024.
Revised 10.01.2025.
Accepted 30.01.2025.
2. Анджелов В.О. Аденовирусные заболевания глаз (этиология, клинико-эпидемиологические особенности, лечение и профилактика): автореф. дис… докт. мед. наук. М.; 1971.Angelov V.O. Adenoviral eye diseases (etiology, clinical and epidemiological features, treatment and prevention): thesis. Moscow; 1971 (in Russ.).
3. Muto T., Imaizumi S., Kamoi K. Viral Conjunctivitis. Viruses. 2023;15(3):676. DOI: 10.3390/v15030676
4. Fuchs E. Keratitis punctata superficialis. Wien Klin Wochenschr. 1889;44:837–842.
5. Asena L., Şıngar Ozdemir E., Burcu A. et al. Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis. Eye (Lond). 2017;31(5):781–787. DOI: 10.1038/eye.2017.4
6. Руководство по вирусологии: Вирусы и вирусные инфекции человека и животных. Под ред. Львова Д.К. М.: Медицинское информационное агентство; 2013.Viruses and viral infections in humans and animals. L'vov D.K., ed. Moscow: Meditsinskoe informatsionnoe agentstvo; 2013 (in Russ.).
7. Кочергин С.А., Чернакова Г.М., Клещева Е.А., Семенова Т.Б. Современные подходы к терапии вирусных и невирусных конъюнктивитов. Российский офтальмологический журнал. 2014;7(4):32–39.Kochergin S.A., Chernakova G.M., Kleshcheva E.A., Semenova T.B. Modern approaches to the treatment of viral and nonviral conjunctivitis. Russian Ophthalmological Journal. 2014;4:32–39 (in Russ.).
8. Веселова E.B., Каменских Т.Г., Киселев А.В. и др. Результаты клинического исследования эффективности и безопасности препарата Панавир® в терапии постпервичного герпетического кератита. Саратовский научно-медицинский журнал. Приложение: Офтальмология. 2022;18(4):657–661.Veselova E.V., Kamenskikh T.G., Kiselev A.V. et al. Results of a clinical study of the efficacy and safety of Panavir® in the therapy of post-primary herpetic keratitis. Saratov Journal of Medical Scientific Research. Supplement: Ophthalmology. 2022;18(4):657–661 (in Russ.).
9. Яни Е.В., Каменских Т.Г., Веселова Е.В. и др. Эффективность нового противовирусного препарата растительного происхождения в виде глазных капель в комплексной терапии офтальмогерпеса. Российский офтальмологический журнал. 2023;16(3):104–110. DOI: 10.21516/2072-0076-2023-16-3-104-110Yani E.V., Kamenskikh T.G., Veselova E.V. et al. The effectiveness of a new antiviral drug of plant origin in the form of eye drops in the complex therapy of ophthalmic herpes. Russian Ophthalmological Journal. 2023;16(3):104–110 (in Russ.). DOI: 10.21516/2072-0076-2023-16-3-104-110
10. Алимбарова Л.М., Лазаренко А.А., Киселев А.В. и др. Оценка эффективности применения экстракта побегов Solanum tuberosum при экспериментальном офтальмогерпесе. Вестник офтальмологии. 2015;131(3):76–81.Alimbarova L.M., Lazarenko A.A., Kiselev A.V. et al. Evaluating the effectiveness of Solanum tuberosum shoots extract in experimental ocular herpes. Russian Annals of Ophthalmology. 2015;131(3):76–81 (in Russ.). DOI: 10.17116/oftalma2015131376-81
11. Веселова Е.В., Каменских Т.Г., Шаденков Д.А. и др. Результаты клинического исследования эффективности и безопасности препарата Панавир® в терапии кератоконъюнктивита аденовирусной этиологии. Саратовский научно-медицинский журнал. Приложение: Офтальмология. 2022;18(4):662–667.Veselova E.V., Kamenskikh T.G., Shadenkov D.A et al. Results of a clinical study of the efficacy and safety of Panavir® in the treatment of keratoconjunctivitis of adenovirus etiology. Saratov Journal of Medical Scientific Research. Supplement: Ophthalmology. 2022;18(4):662–667 (in Russ.).
12. Грибенча С.В., Литвин А.А., Кохнович М.А. и др. Защитная активность препарата Панавир при экспериментальной рабической инфекции. Антибиотики и химиотерапия. 2009;54(5–6):31–36.Gribencha S.V., Litvin A.A., Kokhnovich M.A. et al. Protective Activity of Panavir in Experimental Rabies Infection. Antibiotics and Chemotherapy. 2009;54(5-6):31–36 (in Russ.).
13. Лепехин А.В., Ратникова Л.И., Литвин А.А. и др. Опыт применения Панавира в терапии клещевого энцефалита. Инфекционные болезни. 2007;5(1):41–46.Lepekhin A.V., Ratnikova L.I., Litvin A.A. et al. An experience of using Panavir in therapy of tick-borne encephalitis. Infectious diseases. 2007;5(1):41–46 (in Russ.).
14. Kalinina T.S., Zlenko D.V., Kiselev A.V. et al. Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir®). Int J Biol Macromol. 2020;161:936–938. DOI: 10.1016/j.ijbiomac.2020.06.031
15. Palay D.A., Krachmer J.H. Ophthalmology for the primary care physician. St. Louis: Mosby; 1997.
16. Клещева Е.А. Острые и хронические формы аденовирусной инфекции глаз (клинико-иммунологическое исследование): автореф. дис. … канд. мед. наук. М.; 2012.Kleshcheva E.A. Acute and chronic forms of adenovirus eye infection (clinical and immunological examination): abstract of the dissertation: thesis. Moscow; 2012 (in Russ.).
17. Martínez J., López L.R., Merino P. Antiviral activities of polysaccharides from natural sources. Stud Nat Prod Chem. 2005;30:393–418. DOI: 10.1016/S1572-5995(05)80038-9
18. Wang W., Wang S.-X., Guan H.-S. The Antiviral Activities and Mechanisms of Marine Polysaccharides: An Overview. Marine Drugs. 2012;10(12):2795–2816. DOI: 10.3390/md10122795
This work is licensed under a Creative Commons «Attribution» 4.0 License.
